• Gwénaël Ferron, Alejandra Martinez, Eliane Mery, Denis Querleu, Fabienne Thomas, Etienne Chatelut, and Laurence Gladieff.
• Departement de Chirurgie Oncologique, EA3035, Departement d'Anatomo-Pathologie, Université de Toulouse, Departement d'Oncologie Médicale Institut Claudius-Regaud, 20-24 Rue du Pont-Saint-Pierre, 31052 Toulouse Cedex. ferron.gwenael@claudiusregaud.fr
• Bull Cancer. 2009 Dec 1;96(12):1243-52.

AbstractHyperthermic intraperitoneal chemotherapy (HIPEC) represents a new treatment strategy aimed to improve outcome of patients with advanced ovarian cancer. Based on theoretical and experimental basis, HIPEC should stand as an effective treatment for ovarian cancer. Literature review reveals a number of different experiences on feasibility of this technique, but scientific evidence of current studies remains poor. Much more research is still required to elucidate unanswered questions. Before this technique can be routinely used, some controversial aspects have to be defined: which drug is the best to deliver and at what temperature, is it necessary to use mono- or poly-chemotherapy regimens, which is the time-point for HIPEC in the natural history of ovarian cancer: at front-line therapy, at interval debulking following initial neo-adjuvant chemotherapy, at consolidation following front-line therapy, or at the time of recurrence. Nevertheless, we must not forget that the most important issue in ovarian cancer prognosis is maximal cytoreductive surgery, with no residual disease at completion of initial surgery.

31 keywords...

hide…